Literature DB >> 12879986

Drug-induced cholestasis.

Cynthia Levy1, Keith D Lindor.   

Abstract

Drug-induced cholestasis is a common entity, seen with numerous classes of pharmacological agents. A high index of suspicion is required for the correct diagnosis. Different clinical syndromes may be recognized, with variable degrees of hepatitis in association with cholestasis. The most important aspect of treatment is prompt discontinuation of the offending drug. Several agents have been used for symptomatic relieve of the pruritus associated with cholestasis, including cholestyramine, ursodeoxycholic acid, and opiate antagonists, with limited results. Prognosis is usually good, with few cases of prolonged cholestasis leading to vanishing bile duct syndrome. Liver failure may rarely occur if diagnosis goes unrecognized and the inciting drug is not withdrawn.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879986     DOI: 10.1016/s1089-3261(03)00032-1

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  5 in total

1.  Updated study on risk of cholestatic liver disease and flucloxacillin.

Authors:  Lin Li; Hershel Jick; Susan S Jick
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 2.  An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.

Authors:  Kyunghee Yang; Kathleen Köck; Alexander Sedykh; Alexander Tropsha; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2013-05-07       Impact factor: 3.534

3.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

Review 4.  Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.

Authors:  Jason C White; Stephanie Appleman
Journal:  Pediatrics       Date:  2014-09-22       Impact factor: 7.124

5.  Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.

Authors:  Robert J Fontana; Paul H Hayashi; Huiman Barnhart; David E Kleiner; K Rajender Reddy; Naga Chalasani; William M Lee; Andrew Stolz; Thomas Phillips; Jose Serrano; Paul B Watkins
Journal:  Am J Gastroenterol       Date:  2015-09-08       Impact factor: 10.864

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.